Determinación de factores de riesgo a reacciones adversas a medicamentos mediante farmacovigilancia intensiva en UCI



Título del documento: Determinación de factores de riesgo a reacciones adversas a medicamentos mediante farmacovigilancia intensiva en UCI
Revista: lRevista médica de Chile
Base de datos: PERIÓDICA
Número de sistema: 000449351
ISSN: 0034-9887
Autores: 1
1
2
Instituciones: 1Pontificia Universidad Católica de Chile, Facultad de Química y Farmacia, Santiago de Chile. Chile
2Pontificia Universidad Católica de Chile, Facultad de Medicina, Santiago de Chile. Chile
Año:
Volumen: 149
Número: 9
Paginación: 1258-1266
País: Chile
Idioma: Español
Tipo de documento: Artículo
Enfoque: Analítico, descriptivo
Resumen en inglés Patients hospitalized in intensive care units (ICU) are at higher risk of having adverse drug reactions (ADR). Aim: To determine risk factors for ADR, through intensive pharmacological surveillance at the ICU. Patients and Methods: An observational, descriptive and prospective study was made, determining risk parameters in patients who experienced ADR. Results: Eighty-five patients were surveilled and 24 (28%) had an ADR. A total of 48 drugs responsible for at least one ADR were identified. Seventy-three percent ADR were moderate and 27% were severe. The clinical variables significantly associated with ADR were a history of allergies, a high body mass index, the reason for admission, an APACHE II score ≥ 14 points, the use of invasive mechanical ventilation and more than seven days of hospitalization. The pharmacological variables associated with ADR were polypharmacy and medication associations and combinations. Conclusions: The identified risk factors have a great impact on pharmacokinetic and pharmacodynamic parameters, and should be considered to avoid the appearance of ADR
Disciplinas: Medicina
Palabras clave: Farmacología,
Hospitales,
Interacciones farmacológicas,
Reacciones adversas,
Polifarmacia,
Farmacovigilancia
Keyword: Pharmacology,
Hospitals,
Drug interactions,
Adverse reactions,
Polypharmacy,
Pharmacovigilance
Texto completo: Texto completo (Ver HTML) Texto completo (Ver PDF)